Whilst the mitochondria-targeted Kv1.3 inhibitors PCARBTP and PAPTP have proven their efficacy and lack of side effects in in vivo models of melanoma and pancreatic adenocarcinoma, BBB hinders their action against brain tumors. This evidence concerns the gene KCNA3 and melanoma.